A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax (rHuIL-12) in Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2016
At a glance
- Drugs NMIL 12 1 (Primary)
- Indications Acute radiation syndrome
- Focus Adverse reactions
- Sponsors Neumedicines
- 02 Aug 2016 Status changed from active, no longer recruiting to completed.
- 19 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Sep 2015 Planned End Date changed from 1 May 2015 to 1 Aug 2016, as reported by ClinicalTrials.gov.